
medicines
patent
pool

medicines
patent
pool

UPDATE ON PROGRESS OF MPP SUBLICENSEES

(till December 2021)

SUMMARY

This presentation showcases the progress made by MPP licensees (generic pharmaceutical companies).

To date, MPP has signed agreements with 13 patent holders for 13 HIV antiretrovirals, 1 HIV technology platform, 3 hepatitis C direct-acting antivirals, 1 tuberculosis treatment, 2 long-acting technologies, 2 experimental oral antiviral treatments for COVID-19 and 1 COVID-19 serological antibody diagnostic test.

Licensed products are developed by multiple MPP licensees, with an aim of encouraging competition, reducing market prices and providing faster access to medicines for people living in low- and middle-income countries (LMICs).

Generic medicines are developed and filed with stringent regulatory authorities such as the U.S. Food and Drug Administration (USFDA) and the World Health Organization prequalification (WHO-PQ), ensuring availability of quality assured products in LMICs.

This presentation gives a snapshot of the development of each licensed product and when the product may be filed with regulators. It also shows which countries the local filing is taking place in and when – thereby providing a clearer picture of availability of new formulations in each country.

medicines patent pool

MPP Partnerships With Innovators

abbvie	Boehringer Ingelheim	Bristol-Myers Squibb	GILEAD	janssen	MSD	NIH	ViiV Healthcare
lopinavir ritonavir (adults)	nevirapine (non-assert)	atazanavir	bictegravir	darunavir (paediatric; non-assert)	raltegravir (paediatric)	darunavir related	abacavir (paediatric)
lopinavir ritonavir (paediatric)			cobicistat				dolutegravir (paediatric)
			elvitegravir				dolutegravir (adults)
			emtricitabine				dolutegravir (adults, for AZ, BY, KZ, MY)
			tenofovir alafenamide				
			tenofovir disoproxil fumarate				

abbvie	Bristol-Myers Squibb	PHARCO CORPORATION	JOHNS HOPKINS UNIVERSITY	Pfizer	MSD	Pfizer	UNIVERSITY OF LIVERPOOL	UNIVERSITY of WASHINGTON	CSIC
glecaprevir/ pibrentasvir	daclatasvir	ravidasvir	sutezolid	molnupiravir	nirmatrelvir		solid drug nanoparticles technology (disease agnostic)	TLD LAI (HIV)	serological antibody diagnostic test (COVID-19)
							ETFD LAI (TB, malaria, HCV)		

HIV · Hepatitis C · Tuberculosis · COVID-19 · Technologies (e.g., long-acting, diagnostics)

MPP Partnerships With Generics

abacavir (paed)

- AUROBINDO

atazanavir

- AUROBINDO
- Cipla
- DESANO 迪赛诺
- Emcure
- Mylan

bictegravir

- adcock ingram
- Arene Lifesciences Limited
- AUROBINDO
- 安徽贝克 ANHUI BIOCHEM
- DESANO 迪赛诺
- Emcure
- LAURUS Labs
- LUPIN
- MACLEODS

cobicistat

- adcock ingram
- Arene Lifesciences Limited
- 安徽贝克 ANHUI BIOCHEM
- Emcure
- LUPIN

dolutegravir

- adcock ingram **
- Arene Lifesciences Limited
- CELLTRION **
- Cipla **
- DESANO 迪赛诺 **
- Emcure **
- HETERO **
- LANGHUA 朗华制药
- ** LAURUS Labs
- LUPIN **
- ** MACLEODS
- MANGALAM
- MICRO LABS LIMITED **
- ** Mylan
- ** Strides
- SUN PHARMA **

elvitegravir

- adcock ingram
- Arene Lifesciences Limited
- 安徽贝克 ANHUI BIOCHEM

emtricitabine

- adcock ingram
- Arene Lifesciences Limited
- AUROBINDO
- 安徽贝克 ANHUI BIOCHEM
- DESANO 迪赛诺
- Emcure
- LAURUS Labs
- LUPIN
- MACLEODS
- MICRO LABS LIMITED
- NATCO

lopinavir, ritonavir

- adcock ingram
- Arene Lifesciences Limited
- AUROBINDO
- Cipla *
- DESANO 迪赛诺
- Emcure
- HETERO
- LUPIN
- SUN PHARMA

raltegravir Paed

- LUPIN

tenofovir alafenamide

- adcock ingram
- Arene Lifesciences Limited
- AUROBINDO
- 安徽贝克 ANHUI BIOCHEM
- DESANO 迪赛诺
- Emcure
- LANGHUA 朗华制药
- LAURUS Labs
- LUPIN
- MACLEODS
- MICRO LABS LIMITED
- NATCO

tenofovir disoproxil fumarate

- adcock ingram
- Arene Lifesciences Limited
- 安徽贝克 ANHUI BIOCHEM

daclatasavir

- BEXIMCO PHARMA
- Cipla
- HETERO
- LAURUS Labs
- Mylan
- NATCO
- Zydus Cadila

glecaprevir/ pibrentasvir

- Arene Lifesciences Limited
- Mylan
- Remington
- USV

molnupiravir

- Arene Lifesciences Limited
- aspen
- BDR
- BEXIMCO PHARMA
- Biophore
- BrightGene 博瑞医药
- CELLTRION
- CPT Pharma
- DESANO 迪赛诺
- DONGBANG FTL
- FOSUN PHARMA
- kimia farma
- Hanmi Pharm.
- hikma.
- Incepta
- LANGHUA 朗华制药
- LAURUS Labs
- LONZEAL 龙泽制药
- LUPIN
- MSN
- NATCO
- Optimus
- Remington
- sms pharmaceuticals ltd
- STELLA
- Strides
- UNIVERSAL

nirmatrelvir

- amneal
- APELOA 普洛
- Arene Lifesciences Limited
- AUROBINDO
- BEXIMCO PHARMA
- Biocon
- CADILA PHARMACEUTICALS
- CELLTRION
- Cipla
- DARNITSA
- DESANO 迪赛诺
- Divis
- DONGBANG FTL
- Emcure
- FOSUN PHARMA
- glenmark LIFE SCIENCES
- glenmark
- GRANULES
- HETERO
- hikma.
- 华海药业 HUAHAI PHARMACEUTICAL
- JIUZHOU Pharmaceutical
- LAURUS Labs
- MACLEODS
- Magnachem
- MSN
- Mylan
- NEOLPHARMA
- NORTEC QUÍMICA
- Remington
- sms pharmaceuticals ltd
- STELLA
- Strides
- SUN PHARMA
- teva
- torrent PHARMA
- ZDRAVLJE

sutezolid John Hopkins University

- TB ALLIANCE

sutezolid Pfizer

- BILL & MELINDA GATES foundation

* Only LPV/r paed licence ** Also have DTG paed licence

HIV Hepatitis C Tuberculosis COVID-19

TRIANGLE CHARTS: A SNAPSHOT

Triangle charts represent a comparative analysis of each MPP licensee's filings with WHO-PQ and/or USFDA for each product country



Companies approved ▼ Companies filed ▽ Companies planning to file

Note: *Each triangle represents a manufacturer and timelines represent date of filing*

See following slides for explanation

TRIANGLE CHARTS EXPLAINED (1/7)

Stringent Regulatory Authorities
for filing the product

TRIANGLE CHARTS EXPLAINED (2/7)



TRIANGLE CHARTS EXPLAINED (3/7)



No. of companies that have **received approval out of total companies filed** with WHO-PQ/USFDA

TRIANGLE CHARTS EXPLAINED (4/7)

Total no. of **companies** that **have been approved by** WHO-PQ/USFDA

TRIANGLE CHARTS EXPLAINED (5/7)

Outlined triangles (▽) represent companies **developing the product** and **planning to file** with WHO-PQ and/or USFDA



▽ Companies planning to file

Note: *Each triangle represents a manufacturer and timelines represent date of filing*

TRIANGLE CHARTS EXPLAINED (6/7)

Filled triangles (▼) represent companies who have **completed the product development** and have **filed** with WHO-PQ and/or USFDA



▼ Companies filed

Note: *Each triangle represents a manufacturer and timelines represent date of filing*

TRIANGLE CHARTS EXPLAINED (7/7)

Circled triangles ▼ represent companies who have **completed the product development** and have **received approvals** from WHO-PQ and/or USFDA



▼ **Companies approved**

Note: *Each triangle represents a manufacturer and timelines represent date of filing*

medicines patent pool

DOLUTEGRAVIR



CURRENT SUBLICENSEES FOR VIIV-MPP DOLUTEGRAVIR LICENCE

16 dolutegravir sublicensee agreements

DOLUTEGRAVIR

adcock ingram

Arene Lifesciences Limited

CELLTRION

Cipla

DESANO

Emcure
SUCCESS THROUGH INNOVATION

HETERO

LANGHUA
朗华制药

LAURUS Labs
Knowledge . Innovation . Excellence

LUPIN

MACLEODS

MANGALAM

MICRO LABS LIMITED

Mylan

Strides

SUN PHARMA

*Aurobindo is a direct licensee of ViiV. A tripartite agreement Aurobindo-ViiV-MPP has been signed. For the purposes of this presentation only, Aurobindo will be referred to as an MPP licensee.
Note: the following presentation contains updates as of December 2021, however approvals through March 2022 are included.

medicines patent pool

DTG 50mg: FORMULATION DEVELOPMENT TIMELINES



Note: *Each triangle represents a manufacturer and timelines represent date of filing*

11 MPP LICENSEES HAVE DEVELOPED DTG 50MG,OF WHICH: 10 COMPANIES ARE READY TO COMMERCIALIZE THE PRODUCT

Licensees Approved*: Aurobindo, Cipla, Desano, Emcure, Hetero, Laurus, Macleods, Micro Labs, Mylan, Sun Pharma

1 licensee awaiting WHO-PQ approval | **3** licensees awaiting USFDA approval

1 additional licensee developing and plans to file with WHO-PQ in **Q1-23**

*USFDA and/or WHO-PQ

Data as of December 2021

medicines patent pool

DTG 50mg: COUNTRY-WISE FILING STATUS

Generic DTG 50mg has been filed in **69** countries, of which approval has been received in **51** countries

Filings have occurred where **90.7%** of PLHIV^ reside in the licensed territory#

APPROVED (51)
87.8% PLHIV

Anguilla*	Côte d'Ivoire	Kenya	Nigeria	Turks and Caicos Islands*
Antigua and Barbuda*	Dominica*	Kyrgyzstan	Pakistan	Uganda
Bahamas*	Ethiopia	Malawi	Peru*	Ukraine
Barbados*	Ghana	Malaysia	Philippines	Uruguay*
Botswana	Grenada*	Mauritius	Rwanda	Uzbekistan
Burundi	Guatemala	Montserrat*	Saint Lucia*	Zambia
Cambodia	Honduras	Mozambique	Saint Vincent and the Grenadines*	Zimbabwe
Chile*	India	Myanmar	South Africa	
Congo, Dem. Rep	Indonesia	Namibia	Tajikistan	
Congo, Rep	Iran	Nicaragua	Tanzania	
Costa Rica*	Kazakhstan	Niger	Thailand*	

FILED (18)
2.8% PLHIV

Armenia	Jamaica*
Belarus	Mali
Benin	Moldova
Bhutan	Morocco
Burkina Faso	Nepal
Chad	Panama*
El Salvador	Senegal
Gabon	Sri Lanka
Guyana	Vietnam

- New filings and approvals in blue *vis-à-vis last update (Q3-21)*
- Countries where DTG has been sold indicated in **bold type**

* Countries not included in DTG Adult licence but supply by MPP licensees permitted if no patent is being infringed in that country

^ People living with HIV

Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

MPP-ViiV DTG licence agreement

Data as of December 2021

MPP IMPACT MAP: **DTG 50mg**

DTG 50mg sales have occurred in **118** countries in which **98.7%** of PLHIV^ reside in the licensed territory#

DTG adult (50 mg)

Disease: HIV

Worldwide



Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions
^ People living with HIV
# MPP-ViiV DTG licence agreement MPP-ViiV DTG UMICs licence agreement

Data as of December 2021

TDF/3TC/DTG (TLD): FORMULATION DEVELOPMENT TIMELINES



Note: *Each triangle represents a manufacturer and timelines represent date of filing*

13 MPP LICENSEES HAVE DEVELOPED TDF/3TC/DTG, OF WHICH: 12 COMPANIES ARE READY TO COMMERCIALIZE THE PRODUCT

Licensees Approved*: Aurobindo, Celltrion, Cipla, Desano, Emcure, Hetero, Laurus, Lupin, Macleods, Mylan, Strides, Sun Pharma

4 licensees awaiting WHO-PQ approval | **3** licensees awaiting USFDA approval

2 additional licensees developing | One plans to file with WHO in **Q4-22** and another in **Q1-24**

*USFDA and/or WHO-PQ

Data as of December 2021

TDF/3TC/DTG (TLD): COUNTRY-WISE FILING STATUS

Generic TDF/3TC/DTG has been filed in **70** countries, of which approval is received in **52** countries

Filings have occurred where **92.2%** of PLHIV^ reside in the licensed territory#

APPROVED (52)
89.7% PLHIV

Anguilla*	**Chile***	**Indonesia**	**Myanmar**	**Turkmenistan**
Antigua and Barbuda*	**Congo, Dem. Rep**	Kazakhstan	**Namibia**	**Turks and Caicos Islands***
Bahamas*	**Congo, Rep.**	**Kenya**	**Niger**	**Uganda**
Barbados*	**Côte d'Ivoire**	**Kyrgyzstan**	**Nigeria**	**Ukraine**
Belarus	Dominica*	**Madagascar**	**Philippines**	**Uzbekistan**
Benin	**Ethiopia**	**Malawi**	**Rwanda**	**Vietnam**
Botswana	**Gabon**	**Mali**	Saint Lucia*	**Zambia**
Burkina Faso	**Gambia**	**Mauritania**	Saint Vincent and the Grenadines*	**Zimbabwe**
Cambodia	**Ghana**	Mauritius	**South Africa**	
Cameroon	Grenada*	Montserrat*	**Tanzania**	
Chad	**India**	**Mozambique**	**Thailand***	

FILED (18)
2.4% PLHIV

Armenia	Malaysia
Azerbaijan	**Nepal**
Bangladesh	**Nicaragua**
Bhutan	**Peru***
Burundi	**Senegal**
El Salvador	**Sierra Leone**
Guatemala	Sri Lanka
Guinea	**Sudan**
Lebanon*	**Togo**

- New filings and approvals in blue *vis-à-vis last update (Q3-21)*
- Countries where DTG has been sold indicated in **bold type**

* Countries not included in DTG Adult licence but supply by MPP licensees permitted if no patent is being infringed in that country

^ People living with HIV

Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

MPP-ViiV DTG licence agreement

Data as of December 2021

MPP IMPACT MAP: **TDF/3TC/DTG (TLD)**

TLD sales have occurred in **99** countries in which **99%** of PLHIV^ reside in the licensed territory#

TLD - TDF/3TC/DTG (300/300/50 mg)

Disease: HIV

Worldwide



Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions
^ People living with HIV
# MPP-ViiV DTG licence agreement

Data as of December 2021

DTG & TLD:
COUNTRIES OF SALE- (2017- December 2021)

Countries of Sale (122), where 99.5% of PLHIV^ covered by the license reside#

Afghanistan	Botswana	Ecuador	Honduras	Moldova, Republic of	Rwanda	Timor-Leste
Albania	Burkina Faso	Egypt	India	Mongolia	Saint Kitts and Nevis	Togo
Algeria	Burundi	El Salvador	Indonesia	Montserrat	Saint Lucia	Turkmenistan
Angola	Cabo Verde	Equatorial Guinea	Iran (Islamic Republic of)	Morocco	Saint Vincent and the Grenadines	Turks and Caicos Islands
Anguilla	Cambodia	Eritrea	Jamaica	Mozambique	Sao Tome and Principe	Uganda
Antigua and Barbuda	Cameroon	Eswatini	Kenya	Myanmar	Senegal	Ukraine
Argentina	Central African Republic	Ethiopia	Kosovo	Namibia	Seychelles	Uruguay
Armenia	Chad	Fiji	Kyrgyzstan	Nepal	Sierra Leone	Uzbekistan
Azerbaijan	Chile	Gabon	Lao People's Democratic Republic (the)	Nicaragua	Somalia	Venezuela (Bolivarian Republic of)
Bahamas	Comoros	Gambia	Lebanon	Niger	South Africa	Viet Nam
Bangladesh	Congo	Georgia	Lesotho	Nigeria	South Sudan	Virgin Islands (British)
Barbados	Congo, democratic Republic of the	Ghana	Liberia	Oman	Sri Lanka	Yemen
Belarus	Costa Rica	Grenada	Libya	Pakistan	Sudan	Zambia
Belize	Côte d'Ivoire	Guatemala	Madagascar	Panama	Suriname	Zimbabwe
Benin	Cuba	Guinea	Malawi	Papua New Guinea	Syrian Arab Republic	
Bermuda	Djibouti	Guinea-Bissau	Mali	Paraguay	Tajikistan	
Bhutan	Dominica	Guyana	Mauritania	Peru	Tanzania, United Republic of	
Bolivia	Dominican Republic	Haiti	Mauritius	Philippines	Thailand	

Analysis include sales of DTG 50mg and TDF/3TC/DTG:

● Sales of DTG 50mg only (n=23) ● Sales of TLD only (n=4)

^ People living with HIV
# MPP-ViiV DTG licence agreement

Data as of December 2021

Cumulative Packs Sold: TLD & DTG 50mg (2017- December 2021)

556.1 million packs of TLD and **28.7** million packs of DTG 50mg sold till December 2021



Source: confidential sales data by MPP licensees

Note: Packs of 90's & 180's converted to 30's for this analysis

Data as of December 2021

Patient Equivalents Receiving TDF/3TC/DTG (TLD) Through MPP Licensees

Today, at least **20.3** million people living with HIV (PLHIV) are on MPP-enabled generic TLD[1]

(>80% of PLHIV on ART in LMICs)[2]

Patient Equivalents[2] Receiving TDF/3TC/DTG Supplied Through MPP Licensees per Quarter



Source: confidential sales data by MPP licensees

TLD

Note:. Packs of 90 's and 180's converted to 30's for this analysis. Analysis excludes sales of DTG 50mg singles.

[1] Total PLHIV on TLD-based treatment calculated by dividing total packs sold in the last 4 quarters by 12 (months);

[2] "Patient Equivalents" per quarter calculated by dividing the total packs of TLD sold in a quarter by 3 (months)

[3] Epi data sourced from Consolidated Forecast of Global ARV Demand (WHO): 24,463,415 PLHIV on First Line ART (2021)

Data as of December 2021

TOP COUNTRY RECIPIENTS OF DTG & TLD (2017- December 2021)

Top 20 countries comprise more than 75% of the TLD market in LMICs (by volume)*

Ratio of DTG 50mg:TLD in country-level sales data suggests DTG 50mg is largely being used for **TB-coinfection and/or 2L ART**



Source: confidential sales data by MPP licensees

DTG 50mg TLD (#) Total Packs Sold

* Excludes SSA
**Sub-Saharan Africa (SSA): non-identified countries by which sales were made through procurement agents
Packs of 90's & 180's converted to 30's for this analysis;

Data as of December 2021

Rapid Scale-Up of TLD (2018 – December 2021)

As of December 2021, TLD was supplied in 99 countries by 11 of MPP Partners

9 countries reported TLD sales for the first time in 2021

Cumulative Packs of TDF/3TC/DTG Supplied Through MPP Licensees By Country



Source: confidential sales data by MPP licensees

*Sub-Saharan Africa (SSA): non-identified countries by which sales were made through procurement agents
Packs of 90's & 180's converted to 30's for this analysis;

Data as of December 2021

DTG/3TC:
FORMULATION DEVELOPMENT TIMELINES



Note: *Each triangle represents a manufacturer and timelines represent date of filing*

2 MPP LICENSEES HAVE DEVELOPED DTG/3TC AND ARE AWAITING USFDA APPROVAL

3 additional licensees developing this product | One plans to file in **Q4-22** | Two other plan to file in H1-23

Data as of December 2021

ABC/3TC/DTG (Adult): FORMULATION DEVELOPMENT TIMELINES



6 MPP LICENSEES HAVE DEVELOPED ABC/3TC/DTG ADULT FORMULATION AND LAURUS IS READY TO SUPPLY

Five licensees awaiting USFDA approval

Data as of December 2021

TAF/FTC/DTG (TAF-ED): FORMULATION DEVELOPMENT TIMELINES

Note: *Each triangle represents a manufacturer and timelines represent date of filing*

7 MPP LICENSEES HAVE DEVELOPED TAF/FTC/DTG, OF WHICH: 2 COMPANIES ARE READY TO COMMERCIALIZE THE PRODUCT

Licensees Approved: Laurus, Mylan

5 licensees awaiting USFDA approval | **1** additional licensee developing and plans to file in **Q4-22**

❑ We anticipate development by additional licensees to accelerate, once there is an update on WHO's position about use of TAF-containing formulations

Data as of December 2021

TAF/3TC/DTG (TAF-LD): FORMULATION DEVELOPMENT TIMELINES



Companies approved ▽ Companies planning to file

Note: *Each triangle represents a manufacturer and timelines represent date of filing*

3 MPP LICENSEES HAVE DEVELOPED TAF/3TC/DTG, AND: ALL ARE READY TO COMMERCIALIZE THE PRODUCT

Licensees Approved: Cipla, Laurus, Mylan

2 additional licensees developing this product | One plans to file in **Q2-22** and another in **Q4-22**

- We anticipate development by additional licensees to accelerate, once there is an update on WHO's position about use of TAF-containing formulations

Data as of December 2021

ADDITIONAL FORMULATIONS

TAF/FTC:
FORMULATION DEVELOPMENT TIMELINES



▼ Companies filed ▽ Companies planning to file

Note: *Each triangle represents a manufacturer and timelines represent date of filing*

6 MPP LICENSEES HAVE DEVELOPED TAF/FTC COMBINATION AND ARE AWAITING USFDA APPROVAL

1 additional licensee developing this product and plans to file in **Q2-23**

Note: Gilead has direct licences with additional manufacturers, details of which are not captured here

- We anticipate development by additional licensees to accelerate, once there is an update on WHO's position about use of TAF-containing formulations

Data as of December 2021

ATV/r: FORMULATION DEVELOPMENT TIMELINES



Companies approved ▼ Companies filed

Note: *Each triangle represents a manufacturer and timelines represent date of filing*

5 MPP LICENSEES HAVE DEVELOPED ATV/R, OF WHICH, 3 COMPANIES ARE READY TO SUPPLY THE PRODUCT

Licensees Approved*: Cipla, Emcure, Mylan

2 licensees awaiting WHO-PQ approvals

Approved in 35 countries | Filed in additional 18 countries | Filings have occurred where 90.4% of PLHIV^ reside in the licensed territory#

*USFDA and/or WHO-PQ
^ People living with HIV
# MPP-BMS ATV license agreement

Data as of December 2021

medicines
patent
pool

PAEDIATRIC HIV

PAEDIATRIC PROJECTS

DTG 10mg scored

(dispersible tablets)

- Two MPP licensees have received approval from USFDA (Mylan & Macleods) and WHO-PQ (Macleods) and are ready to supply the product

ABC/3TC/DTG

(60/30/5mg dispersible tablets)

- Five MPP licensees are developing this product combination. Four plan to file either with USFDA or WHO in H2-22 and another in H2-23

Data as of December 2021

medicines
patent
pool

DACLATASVIR



BMS-MPP DACLATASVIR LICENCE: **CURRENT SUBLICENSEES**

7 daclatasvir sublicensee agreements

DACLATASVIR

BEXIMCO PHARMA

Cipla

HETERO

LAURUS Labs
Knowledge . Innovation . Excellence

Mylan

NATCO

Zydus Cadila

Data as of December 2021

DAC 30mg & 60mg:
FORMULATION DEVELOPMENT TIMELINES



Note: *Each triangle represents a manufacturer and timelines represent date of filing*

4 MPP LICENSEES HAVE DEVELOPED DAC 30/60 MG AND ARE READY TO COMMERCIALIZE THE PRODUCT

Licensees Approved: Cipla, Hetero, Laurus, Mylan

Data as of December 2021

DAC 30mg & 60mg: COUNTRY-WISE FILING STATUS

Generic DAC has been filed in **53** countries, of which approval has been received in **37** countries

Filings have occurred where **58.9%** PLHCV^ reside in the licensed territory#

APPROVED (37)
53.9% PLHCV

Benin	Guyana	**Pakistan**
Burkina Faso	**India**	**Philippines**
Burundi	**Indonesia**	Suriname
Cambodia	**Kazakhstan**	**Tanzania**
Cameroon	**Kyrgyzstan**	**Turkmenistan**
Chad	Liberia	Uganda
Congo, Dem. Rep.	Malawi	**Ukraine**
Congo, Rep.	**Malaysia**	**Uzbekistan**
Côte d'Ivoire	**Mongolia**	**Vietnam**
Dominican Republic	Mozambique	Zambia
Ethiopia	**Myanmar**	**Zimbabwe**
Gabon	Nicaragua	
Ghana	**Nigeria**	

FILED (16)
4.9% PLHCV

Azerbaijan	Mali
Belarus	Namibia
Bolivia	**Nepal**
Botswana	Paraguay
Guatemala	**Rwanda**
Haiti	Senegal
Honduras	Thailand
Kenya	Togo

- Countries where either DAC 30mg or DAC 60mg have been sold indicated in **bold type**

^ People living with Hepatitis C

Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

MPP-BMS DAC licence agreement

Data as of December 2021

MPP IMPACT MAP: **DAC 30mg**

MPP licensees have supplied **~180,000** packs* of generic DAC 30mg across:
India, Indonesia, Malaysia, Myanmar, Nepal, Rwanda, Ukraine, Vietnam

DAC (30 mg)

Disease: Hepatitis C

Worldwide



*Packs of 28

Data as of December 2021

MPP IMPACT MAP: **DAC 60mg**

DAC 60mg sales have occurred in **34** countries where MPP licensees have supplied more than **1.2 Million** treatments*, in which **53.2%** of PLHCV^ reside in the licensed territory#

DAC (60 mg)

Disease: Hepatitis C

Worldwide



Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions
^ People living with Hepatitis C
# MPP-BMS DAC licence agreement
**Note: 1 HCV treatment = 12 weeks therapy (3 packs)*

Data as of December 2021

DAC COMMERCIAL LANDSCAPE

3.9 million packs of DAC 30/60mg sold till December 2021



Source: confidential sales data by MPP licensees

Data as of December 2021

TOP COUNTRY RECIPIENTS FOR DAC 30/60mg

DAC has been supplied in **34** countries as of December 2021 by MPP partners. While India constitutes 75% of the volume, 25% can be attributed to the countries shown here.



Source: confidential sales data by MPP licensees

*Non-identified countries are a result of sales made through procurement agencies
** Others include countries in which fewer than 10,000 packs were sold

Data as of December 2021

DAC/SOF: FORMULATION DEVELOPMENT TIMELINES

Note: *Each triangle represents a manufacturer and timelines represent date of filing*

1 MPP LICENSEE (MYLAN) HAS DEVELOPED DAC/SOF AND IS READY TO SUPPLY

Data as of December 2021

DAC/SOF:
COUNTRY-WISE FILING STATUS

Generic DAC/SOF has been filed in **19** countries, of which approval has been received in **13** countries

Filings have occurred where **35.7%** of PLHCV^ reside in the licensed territory#

APPROVED (13) 31.2% PLHCV	
Belarus*	**Myanmar**
Côte d'Ivoire	Nicaragua
Ethiopia	**Nigeria**
Ghana	Suriname
India	**Uganda**
Kenya	Zimbabwe
Malawi	

FILED (6) 4.4% PLHCV	
Guyana	Tanzania
Namibia	**Vietnam**
Paraguay	Zambia

- Countries where DAC/SOF has been sold indicated in **bold type**

*Countries not included in DAC/SOF licence but supply by MPP licensees permitted if no patent is being infringed in that country

^ People living with Hepatitis

Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

MPP-BMS DAC licence agreement

Data as of December 2021

MPP IMPACT MAP: **DAC/SOF**

MPP licensees have supplied more than **100,000** packs* of generic DAC/SOF across:
Burkina Faso, Cambodia, Ethiopia, India, Laos, Myanmar, Nigeria, South Africa, Uganda, Vietnam

DAC+SOF (60/400 mg)

Disease: Hepatitis C

Worldwide



*Packs of 28

Data as of December 2021

medicines
patent
pool

THANK YOU